Heteroresistance to fluconazole in Cryptococcus neoformans is intrinsic and associated with virulence.
about
Yeast: a simple model system to study complex phenomena of aneuploidyCryptococcus gattii infectionsAneuploidy and drug resistance in pathogenic fungiCryptococcus neoformans overcomes stress of azole drugs by formation of disomy in specific multiple chromosomesDeletion of Cryptococcus neoformans AIF ortholog promotes chromosome aneuploidy and fluconazole-resistance in a metacaspase-independent mannerCharacterization of the chromosome 4 genes that affect fluconazole-induced disomy formation in Cryptococcus neoformansFluconazole alters the polysaccharide capsule of Cryptococcus gattii and leads to distinct behaviors in murine CryptococcosisGene Function Analysis in the Ubiquitous Human Commensal and Pathogen Malassezia GenusFungal cytochrome P450 sterol 14α-demethylase (CYP51) and azole resistance in plant and human pathogens.Multilocus sequence typing of serially collected isolates of Cryptococcus from HIV-infected patients in South Africa.Mismatch Repair of DNA Replication Errors Contributes to Microevolution in the Pathogenic Fungus Cryptococcus neoformansCryptococcus neoformans and Cryptococcus gattii, the etiologic agents of cryptococcosis.Contribution of CgPDR1-regulated genes in enhanced virulence of azole-resistant Candida glabrataHigh-dose fluconazole in combination with amphotericin B is more efficient than monotherapy in murine model of cryptococcosis.Heteroresistance of Cryptococcus gattii to fluconazole.Genome-wide expression profiling of the response to short-term exposure to fluconazole in Cryptococcus neoformans serotype ATLR9 signaling is required for generation of the adaptive immune protection in Cryptococcus neoformans-infected lungs.Regulatory circuitry governing fungal development, drug resistance, and disease.Rapid mechanisms for generating genome diversity: whole ploidy shifts, aneuploidy, and loss of heterozygosityCorrelation of anti-fungal susceptibility with clinical outcomes in patients with cryptococcal meningitis.Cryptococcus neoformans Yap1 is required for normal fluconazole and oxidative stress resistanceIdentification of a Cryptococcus neoformans cytochrome P450 lanosterol 14α-demethylase (Erg11) residue critical for differential susceptibility between fluconazole/voriconazole and itraconazole/posaconazole.Involvement of PDK1, PKC and TOR signalling pathways in basal fluconazole tolerance in Cryptococcus neoformans.Heteroresistance to Itraconazole Alters the Morphology and Increases the Virulence of Cryptococcus gattii.Clinical significance of the isolation of Candida species from hospitalized patients.Cryptococcus neoformans Yop1 , an endoplasmic reticulum curvature-stabilizing protein, participates with Sey1 in influencing fluconazole-induced disomy formationAbdominal Lymphonodular Cryptococcosis in an Immunocompetent ChildFluconazole Susceptibility in Cryptococcus gattii Is Dependent on the ABC Transporter Pdr11.Retrospective Study of Cryptococcal Meningitis With Elevated Minimum Inhibitory Concentration to Fluconazole in Immunocompromised Patients.Identification of QTLs Associated with Virulence Related Traits and Drug Resistance in Cryptococcus neoformans.Cryptococcus: from environmental saprophyte to global pathogen.Azole heteroresistance in Cryptococcus neoformans: emergence of resistant clones with chromosomal disomy in the mouse brain during fluconazole treatmentBalancing stability and flexibility within the genome of the pathogen Cryptococcus neoformans.Mechanisms of cryptococcal virulence and persistence.Fluconazole resistance in cryptococcal disease: emerging or intrinsic?Cryptococcosis: epidemiology, fungal resistance, and new alternatives for treatment.Impact of Resistance to Fluconazole on Virulence and Morphological Aspects of Cryptococcus neoformans and Cryptococcus gattii Isolates.The fungal resistome: a risk and an opportunity for the development of novel antifungal therapies.Activity of VT-1129 against Cryptococcus neoformans clinical isolates with high fluconazole MICs.Molecular characterisation and antifungal susceptibility of clinical Cryptococcus deuterogattii (AFLP6/VGII) isolates from Southern Brazil.
P2860
Q27001656-ECB4C482-EF3E-480C-A73A-ECCABA77E458Q27002687-6567CBF1-00C1-41AF-B0C3-D1E2FEA016EBQ27011632-1F4D570D-6D51-4F29-B9DB-FD97DDEFB616Q27315103-E2CEC484-EB93-461E-8B8E-92EA8E0107D8Q28478069-0586964E-57E2-45C6-ADB5-53DAF3F2C2E2Q28481426-49BC984B-C870-40BE-A5AA-0B1D5D924DC9Q28544939-FEC957A1-BC5B-4F0A-9B5A-746350401481Q28817924-7149778A-F7C5-4D84-82E4-967FAF948009Q30318077-1A065DA4-178E-4AFC-8CAE-EC2CBB2E388FQ33703545-E39AAFC3-BBA7-478A-92E0-3D50B3F9B45AQ33741252-177E214A-4629-40BD-8FE1-3341783EC8C4Q33790656-4C5BE935-616F-4B02-A290-0C748E870B80Q33847058-E180ECE2-604C-4B8C-8E39-B8D190835444Q33875911-48BF0C7B-F97B-42FB-A9FB-9CD850A4A8C9Q33876577-5C980EEA-0BB3-426C-A328-9FC394DD10B7Q33898678-CAC8CA80-9ECC-421C-96FD-C1C143F61688Q34033551-FC2674F2-08B9-4141-9EAF-68772AC98D29Q34190284-7566F7D6-55BF-4BEB-99AC-13F060E1D822Q34355333-3C9F05AC-6F4E-4FE1-B3CA-569A65BF5B04Q34518388-821E8999-B6EB-4A87-B258-F83FDA4C4BADQ34943653-9DF0388B-E779-4794-8555-B0DD2A7F0611Q35806201-13AB7E7A-10B7-4D40-BF3B-0E51DD4FD1B0Q35854764-C719D22F-30EA-461C-A694-66C301C1A809Q35860071-5C7A9A92-06CC-43E3-A190-5783B3F0F6E9Q35881281-BDD4D5E7-3E6F-46DE-8AFF-E2ABFA87CA9EQ36319731-C6BADC96-3365-4151-9FBD-064317C665B3Q36328844-43FB048D-7169-4994-8902-4BB0AC314EC8Q36644733-F9F9409A-E20C-4999-BAE2-53C823FEBB20Q37091636-55C6ABF0-7056-4984-A7FB-4F133E64596EQ37242018-5AB8E3BF-1E4F-4DB6-9237-AD8AD8E5A412Q37250158-CC6DA926-DFCA-4BC7-A424-66FB3C767547Q37263749-B7CA5BB5-C6BD-4E56-8DB8-23BC33928D53Q37388615-ADFBA832-0A50-4F3C-B2EA-8F25ED3B6CA9Q37781066-BBEC7682-55BC-472A-855E-238FB47C19A7Q38044487-81440409-5D42-4485-99FE-59068C0DB657Q38154164-12357CCB-6CB6-41AA-AD5B-9C633C26C7FEQ38467366-FE375E5A-ECEC-4F24-828D-DB10B1DEA6CFQ38835045-6C01D451-312A-480F-BC63-7E84D55A3A02Q38852907-1948D144-03B0-48CF-A47A-6C31B7E4B91DQ39064815-BF081A73-72B7-48E4-9246-6A534B6CE71D
P2860
Heteroresistance to fluconazole in Cryptococcus neoformans is intrinsic and associated with virulence.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Heteroresistance to fluconazol ...... and associated with virulence.
@en
Heteroresistance to fluconazol ...... and associated with virulence.
@nl
type
label
Heteroresistance to fluconazol ...... and associated with virulence.
@en
Heteroresistance to fluconazol ...... and associated with virulence.
@nl
prefLabel
Heteroresistance to fluconazol ...... and associated with virulence.
@en
Heteroresistance to fluconazol ...... and associated with virulence.
@nl
P2093
P2860
P356
P1476
Heteroresistance to fluconazol ...... and associated with virulence.
@en
P2093
Edward Sionov
H Martin Garraffo
Kyung J Kwon-Chung
Yun C Chang
P2860
P304
P356
10.1128/AAC.00295-09
P407
P577
2009-05-04T00:00:00Z